-5%
Brigatinib is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC).
- Brigatinib, also known as Alunbrig, is a targeted cancer drug treatment specifically designed for non-small cell lung cancer (NSCLC).
- It is indicated for the treatment of advanced or metastatic NSCLC, but specifically for those with a mutation in the anaplastic lymphoma kinase (ALK) gene. Genetic testing is performed on tissue samples to confirm this gene change.
- Brigatinib is classified as a tyrosine kinase inhibitor (TKI), falling under the category of cancer growth blockers. It works by inhibiting tyrosine kinase proteins, blocking the chemical signals (enzymes) responsible for sending growth signals in cells.
- By blocking these signals, Brigatinib prevents the growth and division of cancer cells.
- Brigatinib is available in tablet form, which should be swallowed whole with a glass of water.
- It can be taken with or without food, and the dosage should strictly follow the instructions provided by the doctor or pharmacist.
- It is crucial not to alter the prescribed dosage unless advised by the healthcare team.
- Brigatinib is typically taken once a day.
- The treatment continues as long as it remains effective, and the side effects are manageable.
- Regular blood tests are conducted before and during the treatment to assess blood cell levels and other substances.
- Monitoring of liver and kidney function is also part of the testing process.
- Blood pressure, heart rate, and ECG (heart trace test) may be monitored at different intervals during the treatment.
- Brigatinib can interact with other medicines and herbal products. It is crucial to inform the healthcare team about all medications, including vitamins and herbal supplements.
- Grapefruit and grapefruit juice consumption should be avoided during treatment, as it may increase side effects.
- Brigatinib contains lactose (milk sugar). Individuals with lactose intolerance should consult their doctor before taking this medicine.
- Brigatinib may pose a risk to a developing fetus. Adequate non-hormonal contraception (such as condoms) is recommended during treatment to prevent pregnancy.
- Women are advised not to become pregnant for 4 months after finishing treatment, and men should avoid fathering a child for 3 months post-treatment.
- The impact of Brigatinib on fertility is not well-defined. Patients concerned about future fertility should discuss this with their doctor before starting treatment.
- Breastfeeding is not recommended during Brigatinib treatment.
- Inform other healthcare providers about ongoing Brigatinib treatment.
- Avoid live vaccines during treatment and for a specified period afterward, depending on the treatment received. The duration should be discussed with the doctor or pharmacist.